Darius Kharabi sold $17k of KALA
CHIEF BUSINESS OFFICER at Kala Pharmaceuticals, Inc.. 20,806 shares at an average of $0.83, traded Oct 22, 2025, filed Oct 24, 2025.
Score components
- +15RoleOfficer
- 0Trade size$17k at market
- +10Share of holdings soldSold 33% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -22.1%, 3m -24.0%, 6m -82.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001893729-25-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 22, 2025 | SOpen-market sale Common Stock | -20,806 | $0.83 | $17k | 41,760 | Oct 24, 2025 |
Related signals
Other insiders at Kala Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | Kala Pharmaceuticals, Inc. | Todd Bazemore SEE REMARKS | $40k 47,768 shares | -57% | |
| 56Moderate | Kala Pharmaceuticals, Inc. | Romulus K Brazzell SEE REMARKS | $39k 46,748 shares | -57% | |
| 61Notable | Kala Pharmaceuticals, Inc. | Mark T Iwicki CHIEF EXECUTIVE OFFICER | $125k 154,894 shares | -60% | |
| 62Notable | Kala Pharmaceuticals, Inc. | Mary Reumuth CHIEF FINANCIAL OFFICER | $28k 33,197 shares | -53% | |
| 53Moderate | KALAsell Kala Pharmaceuticals, Inc. | Baker Bros. Advisors LP other | $1.1M 730,408 shares | -616% | |
| 10Weak | Kala Pharmaceuticals, Inc. | Todd Bazemore SEE REMARKS | $16k 4,058 shares | -5% | |
| 10Weak | Kala Pharmaceuticals, Inc. | Romulus K Brazzell SEE REMARKS | $21k 5,251 shares | -6% | |
| 17Weak | Kala Pharmaceuticals, Inc. | Mark T Iwicki CHIEF EXECUTIVE OFFICER | $53k 13,227 shares | -5% | |
| 17Weak | Kala Pharmaceuticals, Inc. | Mary Reumuth CHIEF FINANCIAL OFFICER | $15k 3,631 shares | -6% | |
| 10Weak | Kala Pharmaceuticals, Inc. | Darius Kharabi CHIEF BUSINESS OFFICER | $18k 4,511 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.